<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04392895</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL20_0296</org_study_id>
    <nct_id>NCT04392895</nct_id>
  </id_info>
  <brief_title>Para Aortic Lymphadenectomy : Always ?</brief_title>
  <acronym>PALA</acronym>
  <official_title>Assesment of Paraaortic Lymphadenectomy in Locally Advanced Cervical Cancer, When no Pathologic Pelvic Lymph Node on PET/CT: Retrospective Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cervical cancer affects more than 3000 new cases per year in France. The treatment of stage
      IB3 to IVA cervical cancer is based on concomitant radio-chemotherapy. The irradiation
      volumes are based, according to current recommendations, on imaging examinations and / or on
      the results of a laparoscopic Para-aortic lymphadenectomy (PAL). There is some risk of false
      negatif with the PET/CT. For this reason, most of the time, PAL is offered when there is no
      pathological paraaortic lymph node on PET/CT. The investigators suppose that this staging
      surgery could be avoid when no pathological pelvic nodes are identified on PET/CT. The
      investigators use a retrospective study, to analyse histological report of systematic PAL,
      comparing to results of pre-operative PET/CT.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 29, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>negative predictive value of PET/CT on para aortic nodes when no pathological pelvic nodes.</measure>
    <time_frame>1 day</time_frame>
    <description>negative predictive value of PET/CT on para aortic nodes when no pathological pelvic nodes.
The intraoperative 3D optical scan gives the tumor localization obtained by radioguided occult lesion localization thanks to pen marking left by the surgeon. The comparison is done by superimposing both acquisitions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>morbidity of PAL</measure>
    <time_frame>1 day</time_frame>
    <description>morbidity of PAL</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Patients with locally advanced cervical cancer</arm_group_label>
    <description>Patients with locally advanced cervical cancer, who had undergone a PAL</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Para Aortic Lymphadenectomy (PAL) by laparoscopy</intervention_name>
    <description>Para Aortic Lymphadenectomy (PAL) by laparoscopy</description>
    <arm_group_label>Patients with locally advanced cervical cancer</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with locally advanced cervical cancer, who had undergone a PAL after a negative
        paraaortic PET CT, between January 2015 and december 2019
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

        - Patients with :

          -  locally advanced cervical cancer,

          -  who undergone PAL

          -  with pre operative PET CT, between January 2015 and december 2019

        Exclusion criteria:

        - patients aged under 18
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martha DURAES, Md</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>GAUTHIER RATHAT</last_name>
    <phone>467336421</phone>
    <phone_ext>33</phone_ext>
    <email>g-rathat@chu-montpllier.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martha DURAES, MD</last_name>
    <phone>631329158</phone>
    <phone_ext>33</phone_ext>
    <email>duraesmartha@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Uhmontpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>RATHAT GAUTHIER, MD</last_name>
      <phone>467336421</phone>
      <phone_ext>33</phone_ext>
      <email>g-rathat@chu-montpellier.fr</email>
    </contact>
    <contact_backup>
      <last_name>DURAES Martha</last_name>
      <phone>631329158</phone>
      <phone_ext>33</phone_ext>
      <email>duraesmartha@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 13, 2020</study_first_submitted>
  <study_first_submitted_qc>May 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2020</study_first_posted>
  <last_update_submitted>May 20, 2020</last_update_submitted>
  <last_update_submitted_qc>May 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Locally advanced cervical cancer, more than IB3 stage FIGO 2018</keyword>
  <keyword>Para aortic lymphadenectomy</keyword>
  <keyword>Laparoscopy</keyword>
  <keyword>PET/CT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

